Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced 2016 Financial Calendar.
- Yearly end financial report 2015: 24 March 2016
- Annual General Meeting: 5 May 2016
- Q1 2016 Business update: 19 May 2016
- Half year results H1 2016: 25 August 2016
- Q3 2016 Business update: 18 November 2016
